JP2020522254A5 - - Google Patents

Info

Publication number

JP2020522254A5

JP2020522254A5 JP2019566237A JP2019566237A JP2020522254A5 JP 2020522254 A5 JP2020522254 A5 JP 2020522254A5 JP 2019566237 A JP2019566237 A JP 2019566237A JP 2019566237 A JP2019566237 A JP 2019566237A JP 2020522254 A5 JP2020522254 A5 JP 2020522254A5

Authority

JP

Japan

Prior art keywords

mpl

amino acid

chain variable

polypeptide

heavy chain

Prior art date

2018-05-31

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 102100034196 Thrombopoietin receptor Human genes 0.000 claims description 151
• 230000008685 targeting Effects 0.000 claims description 59
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 56
• 229920001184 polypeptide Polymers 0.000 claims description 54
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 54
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 49
• 239000000427 antigen Substances 0.000 claims description 43
• 102000036639 antigens Human genes 0.000 claims description 43
• 108091007433 antigens Proteins 0.000 claims description 43
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims description 23
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims description 23
• 206010028980 Neoplasm Diseases 0.000 claims description 21
• 210000004027 cell Anatomy 0.000 claims description 16
• 201000011510 cancer Diseases 0.000 claims description 13
• 239000012634 fragment Substances 0.000 claims description 11
• 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 10
• 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 10
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 9
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 9
• 238000006471 dimerization reaction Methods 0.000 claims description 9
• 101000606506 Homo sapiens Receptor-type tyrosine-protein phosphatase eta Proteins 0.000 claims description 7
• 102100039808 Receptor-type tyrosine-protein phosphatase eta Human genes 0.000 claims description 7
• 102000006452 Class 5 Receptor-Like Protein Tyrosine Phosphatases Human genes 0.000 claims description 6
• 108010044213 Class 5 Receptor-Like Protein Tyrosine Phosphatases Proteins 0.000 claims description 6
• 210000002865 immune cell Anatomy 0.000 claims description 5
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
• 206010025323 Lymphomas Diseases 0.000 claims description 4
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
• 108091005735 TGF-beta receptors Proteins 0.000 claims description 4
• 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims description 4
• 239000005557 antagonist Substances 0.000 claims description 4
• 239000008194 pharmaceutical composition Substances 0.000 claims description 4
• 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
• 108010044260 Class 2 Receptor-Like Protein Tyrosine Phosphatases Proteins 0.000 claims description 3
• 102000006442 Class 2 Receptor-Like Protein Tyrosine Phosphatases Human genes 0.000 claims description 3
• 102000004127 Cytokines Human genes 0.000 claims description 3
• 108090000695 Cytokines Proteins 0.000 claims description 3
• 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 claims description 3
• 101001048716 Homo sapiens ETS domain-containing protein Elk-4 Proteins 0.000 claims description 3
• 101001092930 Homo sapiens Prosaposin Proteins 0.000 claims description 3
• 101000694802 Homo sapiens Receptor-type tyrosine-protein phosphatase T Proteins 0.000 claims description 3
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 3
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
• -1 RPTPδ Proteins 0.000 claims description 3
• 102100039664 Receptor-type tyrosine-protein phosphatase H Human genes 0.000 claims description 3
• 102100028645 Receptor-type tyrosine-protein phosphatase T Human genes 0.000 claims description 3
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
• 239000000430 cytokine receptor antagonist Substances 0.000 claims description 3
• 210000000265 leukocyte Anatomy 0.000 claims description 3
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
• 108010032595 Antibody Binding Sites Proteins 0.000 claims description 2
• 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 2
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
• 241000282836 Camelus dromedarius Species 0.000 claims description 2
• 102000004190 Enzymes Human genes 0.000 claims description 2
• 108090000790 Enzymes Proteins 0.000 claims description 2
• 208000017604 Hodgkin disease Diseases 0.000 claims description 2
• 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
• 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
• 239000003795 chemical substances by application Substances 0.000 claims description 2
• 230000009881 electrostatic interaction Effects 0.000 claims description 2
• 201000003444 follicular lymphoma Diseases 0.000 claims description 2
• 201000009277 hairy cell leukemia Diseases 0.000 claims description 2
• 238000002372 labelling Methods 0.000 claims description 2
• 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 2
• 208000021937 marginal zone lymphoma Diseases 0.000 claims description 2
• 239000003053 toxin Substances 0.000 claims description 2
• 231100000765 toxin Toxicity 0.000 claims description 2
• 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 8
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
• 230000036210 malignancy Effects 0.000 claims 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
• 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
• 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
• 101001014566 Homo sapiens Membrane-spanning 4-domains subfamily A member 3 Proteins 0.000 claims 1
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
• 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
• 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 1
• 102100032517 Membrane-spanning 4-domains subfamily A member 3 Human genes 0.000 claims 1
• 208000034578 Multiple myelomas Diseases 0.000 claims 1
• 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
• 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
• 230000001154 acute effect Effects 0.000 claims 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
• 208000003747 lymphoid leukemia Diseases 0.000 claims 1
• 239000000825 pharmaceutical preparation Substances 0.000 claims 1
• 229940127557 pharmaceutical product Drugs 0.000 claims 1
• 238000006467 substitution reaction Methods 0.000 description 42
• 102100024952 Protein CBFA2T1 Human genes 0.000 description 40
• 230000004048 modification Effects 0.000 description 40
• 238000012986 modification Methods 0.000 description 40
• 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 21
• 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 21
• 150000001413 amino acids Chemical class 0.000 description 20
• 238000012217 deletion Methods 0.000 description 20
• 230000037430 deletion Effects 0.000 description 20
• 238000003780 insertion Methods 0.000 description 20
• 230000037431 insertion Effects 0.000 description 20
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
• 108060003951 Immunoglobulin Proteins 0.000 description 7
• 102000018358 immunoglobulin Human genes 0.000 description 7
• 230000035772 mutation Effects 0.000 description 6
• 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 5
• 230000000694 effects Effects 0.000 description 5
• 238000000034 method Methods 0.000 description 5
• 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 5
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• 239000012636 effector Substances 0.000 description 3
• 206010028537 myelofibrosis Diseases 0.000 description 3
• 108020004707 nucleic acids Proteins 0.000 description 3
• 102000039446 nucleic acids Human genes 0.000 description 3
• 150000007523 nucleic acids Chemical class 0.000 description 3
• 108020003175 receptors Proteins 0.000 description 3
• 102000005962 receptors Human genes 0.000 description 3
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
• 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
• 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 239000002876 beta blocker Substances 0.000 description 2
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
• 239000013598 vector Substances 0.000 description 2
• 206010016654 Fibrosis Diseases 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
• 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 1
• 101710084191 TGF-beta receptor type-1 Proteins 0.000 description 1
• 102000036693 Thrombopoietin Human genes 0.000 description 1
• 108010041111 Thrombopoietin Proteins 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 230000014509 gene expression Effects 0.000 description 1
• 230000002489 hematologic effect Effects 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 238000000908 micropen lithography Methods 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 208000011580 syndromic disease Diseases 0.000 description 1